Business Context and Reporting Period
Company: Onto Innovation Inc.
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended January 3, 2026 (53-week year).
Business Overview: Onto Innovation is a global leader in metrology and inspection tools for the semiconductor industry, serving front-end wafer manufacturing and back-end advanced packaging. The company operates as a single reportable segment.
Key Financial Metrics
| Metric | Fiscal 2025 (Ended Jan 3, 2026) | Fiscal 2024 (Ended Dec 28, 2024) |
|---|---|---|
| Revenue | $1,005.3 million | $987.3 million |
| Gross Profit | $499.8 million | $515.3 million |
| Gross Margin | 49.7% | 52.2% |
| Operating Income | $132.9 million | $187.1 million |
| Net Income | $136.8 million | $201.7 million |
| Diluted EPS | $2.78 | $4.06 |
| Operating Cash Flow | $328.3 million | $245.7 million |
| Cash & Marketable Securities | $639.6 million | $852.3 million |
| Debt | None (Unutilized $100M credit line) | None |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 2% year-over-year, driven by higher sales to NAND and OSAT customers and revenue from the Semilab USA acquisition. This was partially offset by lower sales to Foundry and DRAM customers.
- Margin Compression: Gross margin declined 250 basis points to 49.7%. The decrease was primarily due to inventory write-downs for excess and obsolete stock, restructuring costs related to infrastructure transitions, and contract manufacturing setup costs.
- Expense Increases: Total operating expenses rose to $366.8 million (from $328.2 million) due to restructuring expenses, transaction and amortization costs from the Semilab USA acquisition, and increased R&D and compensation costs.
- Profitability: Net income decreased 32% to $136.8 million, reflecting the margin pressure and increased operating expenses despite revenue growth.
- Geographic Shift: Revenue from China decreased to 7% of total revenue (from 12% in 2024) due to U.S. export controls. Taiwan and South Korea remained the largest markets at 32% and 28%, respectively.
Guidance, Outlook, and Risks
- Acquisition Integration: The company acquired Semilab USA in Q4 2025 for a total consideration of approximately $526.6 million. This adds three product lines (FAaST, CnCV, MBIR) enhancing capabilities in wafer contamination monitoring and materials characterization. Integration risks include potential disruption to operations and failure to realize anticipated synergies.
- Export Controls: U.S. export regulations continue to impact sales to domestic customers in China, resulting in lower net sales in that region. The company faces risks of further restrictions or delays in obtaining export licenses.
- Supply Chain: The company faces risks related to supply chain delays, shortages, and cost increases (tariffs, labor, materials) which could lower margins or result in lost sales.
- Customer Concentration: The top three customers accounted for 49% of revenue in 2025 (Customer A: 20%, Customer B: 15%, Customer C: 14%). A reduction in orders from these customers could materially impact results.
- Fiscal Year Change: Effective February 18, 2026, the company changed its fiscal year-end from a 52-53 week year to a calendar year ending December 31.
Investor Verification Checklist
- Inventory Valuation: Verify the adequacy of the reserve for excess and obsolete inventory, which was a primary driver of the gross margin decline.
- Semilab USA Integration: Monitor the progress of integrating Semilab USA and the realization of revenue synergies from the new product lines.
- China Exposure: Assess the ongoing impact of U.S. export controls on revenue from China and the company's ability to secure necessary licenses.
- Restructuring Costs: Track the execution of business transformation projects and the associated one-time costs versus long-term savings.
- Customer Concentration: Evaluate the stability of orders from the top three customers, which collectively represent nearly half of total revenue.